Effect of Nutritional Formula Supplementation on Growth of Prepubertal Children Treated With Stimulants Medications for Attention Deficit Hyperactivity Disorder (ADHD)
Primary Purpose
ADHD - Attention Deficit Disorder With Hyperactivity
Status
Recruiting
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Nutritional supplementation standardized formula.
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for ADHD - Attention Deficit Disorder With Hyperactivity
Eligibility Criteria
Inclusion Criteria:
- Boys aged ≤ 10 years and girls aged ≤ 9 years.
- Children treated with stimulants medications for ADHD for at list 3 months.
- Prepubertal -Tanner stage 1 (gonadarche) (boys: testicular volume < 4, girls: breast at Tanner stage 1)
- Normal weight status: BMI-SDS ≤ 85th percentile for age and gender according to the CDC 2000 growth charts
- Signing inform consent forms
Exclusion Criteria:
- Diagnosis of GH Deficiency or treatment with GH
- Any known chronic disease or dysmorphic syndrome including bone diseases, organic brain diseases, neurological disease, past or current malignancy, chronic cardiac, renal or pulmonary problems
- Any known gastrointestinal disease including malabsorption
- Any known organic reason for growth retardation
- Milk allergy.
- Any chronic treatment with additional medication beside stimulants that might affect appetite, weight, or growth (for example SSRI's).
Sites / Locations
- Schneider children's medical centerRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Nutritional Standardized Supplementation Formula
Placebo
Arm Description
Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
Low caloric formula (Powder added to waster) without added vitamins and minerals
Outcomes
Primary Outcome Measures
height standard deviation score (SDS)
weight standard deviation score
Secondary Outcome Measures
BMI SDS
Fat Mass
Lean body mass
Muscle mass
Change in dietary patterns measured by Child Eating Behaviour Questionnaire
Change in ADHD symptoms measured by Vanderblit ADHD Parent Rating Scale
Change in physical activity patterns measured by physical activity questionnaire
Full Information
NCT ID
NCT04962334
First Posted
June 29, 2021
Last Updated
March 15, 2023
Sponsor
Rabin Medical Center
Collaborators
NG Solutions Ltd
1. Study Identification
Unique Protocol Identification Number
NCT04962334
Brief Title
Effect of Nutritional Formula Supplementation on Growth of Prepubertal Children Treated With Stimulants Medications for Attention Deficit Hyperactivity Disorder (ADHD)
Official Title
Effect of Nutritional Formula Supplementation on Growth of Prepubertal Children Treated With Stimulants Medications for ADHD. A Randomized Double-blind, Placebo-controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 1, 2021 (Actual)
Primary Completion Date
July 2024 (Anticipated)
Study Completion Date
July 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rabin Medical Center
Collaborators
NG Solutions Ltd
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The proposed study is a double blind, randomized, placebo controlled study. The aim of the study is to evaluate the effect of nutritional formula supplementation on growth of prepubertal children treated with stimulants medications of ADHD.
70 Participants treated with stimulants medications of ADHD will be randomly assigned either to the intervention group or the placebo control group. Randomization for the two study groups will be made in a ratio of 1:1. Both participants and study team will be blinded to the type of treatment that each patient will receive during the study. Randomization will be stratified according to gender.
Participants in the intervention groups will be treated with the study formula and participants in the control group will be treated with a placebo low caloric formula (Powder added to water). The study will continue for 6 months of intervention versus active placebo, with additional 6 months (an extension period), in which participants at both groups, the intervention and the placebo, will be offered to continue their participation in the study with the active study supplement.
In addition, 30 prepubertal healthy siblings will be recruited to the study in order to compare baseline eating and physical activity patterns of ADHD children treated with stimulants to their healthy untreated siblings at the same age range. Participants' siblings will only complete once the nutritional and physical activity questionnaire and report height and weight measurements.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
ADHD - Attention Deficit Disorder With Hyperactivity
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
70 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Nutritional Standardized Supplementation Formula
Arm Type
Experimental
Arm Description
Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Low caloric formula (Powder added to waster) without added vitamins and minerals
Intervention Type
Dietary Supplement
Intervention Name(s)
Nutritional supplementation standardized formula.
Intervention Description
Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Low caloric formula (powder added to water) without added vitamins and minerals
Primary Outcome Measure Information:
Title
height standard deviation score (SDS)
Time Frame
at 6 months
Title
weight standard deviation score
Time Frame
at 6 months
Secondary Outcome Measure Information:
Title
BMI SDS
Time Frame
at 6 months
Title
Fat Mass
Time Frame
at 6 months
Title
Lean body mass
Time Frame
at 6 months
Title
Muscle mass
Time Frame
at 6 months
Title
Change in dietary patterns measured by Child Eating Behaviour Questionnaire
Time Frame
At 6 months
Title
Change in ADHD symptoms measured by Vanderblit ADHD Parent Rating Scale
Time Frame
at 6 months
Title
Change in physical activity patterns measured by physical activity questionnaire
Time Frame
at 6 months
Other Pre-specified Outcome Measures:
Title
height SDS
Time Frame
at 12 months
Title
Weight SDS
Time Frame
at 12 months
Title
BMI SDS
Time Frame
at 12 months
Title
Fat mass
Time Frame
at 12 months
Title
Lean body mass
Time Frame
at 12 months
Title
Muscle mass
Time Frame
at 12 months
Title
Change in dietary patterns measured by Child Eating Behaviour Questionnaire
Time Frame
at 12 months
Title
Change in ADHD symptoms measured by Vanderblit ADHD Parent Rating Scale
Time Frame
at 12 months
Title
Change in physical activity measured by physical activity questionnaire
Time Frame
at 12 months
10. Eligibility
Sex
All
Maximum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Boys aged ≤ 10 years and girls aged ≤ 9 years.
Children treated with stimulants medications for ADHD for at list 3 months.
Prepubertal -Tanner stage 1 (gonadarche) (boys: testicular volume < 4, girls: breast at Tanner stage 1)
Normal weight status: BMI-SDS ≤ 85th percentile for age and gender according to the CDC 2000 growth charts
Signing inform consent forms
Exclusion Criteria:
Diagnosis of GH Deficiency or treatment with GH
Any known chronic disease or dysmorphic syndrome including bone diseases, organic brain diseases, neurological disease, past or current malignancy, chronic cardiac, renal or pulmonary problems
Any known gastrointestinal disease including malabsorption
Any known organic reason for growth retardation
Milk allergy.
Any chronic treatment with additional medication beside stimulants that might affect appetite, weight, or growth (for example SSRI's).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Moshe Phillip, Prof
Phone
972-3-9253282
Email
mosheph@clalit.org.il
First Name & Middle Initial & Last Name or Official Title & Degree
Alona Hamou, Msc
Phone
972-3-9253747
Email
alonah@clalit.org.il
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Moshe Phillip, Prof
Organizational Affiliation
Schneider Children's Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Schneider children's medical center
City
Petach Tikva
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Moshe Phillip, Prof
Phone
972-39253282
Email
mosheph@clalit.org.il
First Name & Middle Initial & Last Name & Degree
Naama Fish, Dr.
First Name & Middle Initial & Last Name & Degree
Liora Lazar, Prof.
12. IPD Sharing Statement
Learn more about this trial
Effect of Nutritional Formula Supplementation on Growth of Prepubertal Children Treated With Stimulants Medications for Attention Deficit Hyperactivity Disorder (ADHD)
We'll reach out to this number within 24 hrs